- Microbix (MBX) and SpeeDx have formed an exclusive collaboration focusing on diagnostic tests
- Microbix will develop quality assessment products to facilitate the registration and commercialization of SpeeDx diagnostic assays
- The collaboration will begin with SpeeDx’s tests for antimicrobial-resistant strains of mycoplasma genitalium
- The sexually-transmitted infection’s test market is expected to exceed US$1 billion globally by 2027
- SpeeDx is an Australian private company that specializes in molecular diagnostics for improved patient management
- Microbix Biosystems develops proprietary biological technology solutions for human health and wellbeing
- Microbix (MBX) is up by 1.47 per cent and is currently trading at C$0.69 per share
Microbix (MBX) and SpeeDx have formed an exclusive collaboration focusing on diagnostic tests.
Under the collaboration, Microbix will develop quality assessment products to facilitate the registration and commercialization of SpeeDx diagnostic assays.
The collaboration will begin with SpeeDx’s tests for antimicrobial-resistant strains of mycoplasma genitalium, a widespread sexually-transmitted infection with a test market expected to exceed US$1 billion globally by 2027.
The next-generation diagnostics SpeeDx is developing can detect mutations that drive drug resistance, enabling more effective treatment.
In turn, Microbix technology can produce QAPs to support tests for AMR and XDR organisms safely, economically and in large quantities.
Phil Casselli, SVP of Business Development at Microbix, remarked,
“AMR and XDR infections are a dangerous evolution that are leading to challenges in infection control and treatment. We’re therefore very pleased to help SpeeDx to bring their extremely valuable new diagnostic tests to the market.”
Colin Denver, CEO of SpeeDx, added,
“SpeeDx is a world-leader in creating the next-generation assays needed to effectively diagnose and treat drug-resistant bacterial and viral infections. So it makes great sense to work with Microbix and apply its innovative and proprietary controls to ensure the best-possible accuracy of our tests. We believe this alliance will be of great benefit to healthcare globally.”
SpeeDx is an Australian private company that specializes in molecular diagnostics for improved patient management.
Microbix Biosystems develops proprietary biological technology solutions for human health and wellbeing.
Microbix (MBX) is up by 1.47 per cent and is currently trading at C$0.69 per share as of 9:31 am ET.
